References
- Hsu PD, Lander ES, Zhang F. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell. [Internet]. 2014;157:1262–1278. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0092867414006047
- Sontheimer EJ, Barrangou R. The Bacterial Origins of the CRISPR Genome-Editing Revolution. Hum Gene Ther. [Internet]. 2015;26:413–424. .
- Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. [Internet]. 2018;9:1911. Available from: http://www.nature.com/articles/s41467-018-04252-2
- Yamamoto T, Moerschell RP, Wakem LP, et al. Strand-specificity in the transformation of yeast with synthetic oligonucleotides. Genetics. [Internet]. 1992;131:811–819. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1205094%7B&%7Dtool=pmcentrez%7B&%7Drendertype=abstract
- Moerschell RP, Tsunasawa S, Sherman F. Transformation of yeast with synthetic oligonucleotides. Proc Natl Acad Sci U S A. [Internet]. 1988;85:524–528. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=279583%7B&%7Dtool=pmcentrez%7B&%7Drendertype=abstract
- Aarts M, te Riele H. Progress and prospects: oligonucleotide-directed gene modification in mouse embryonic stem cells: a route to therapeutic application. Gene Ther. [Internet]. 2011;18:213–219. Available from: http://www.nature.com/articles/gt2010161
- Parekh-Olmedo H, Ferrara L, Brachman E, et al. Gene therapy progress and prospects: targeted gene repair. Gene Ther. [Internet]. 2005;12:639–646. Available from: http://www.nature.com/articles/3302511
- Dekker M, Brouwers C, Aarts M, et al. Effective oligonucleotide-mediated gene disruption in ES cells lacking the mismatch repair protein MSH3. Gene Ther. [Internet]. 2006;13:686–694. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16437133
- Papaioannou I, Disterer P, Owen JS. Use of internally nuclease-protected single-strand DNA oligonucleotides and silencing of the mismatch repair protein, MSH2, enhances the replication of corrected cells following gene editing. J Gene Med. [Internet]. 2009;11:267–274. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19153972
- Morozov V, Wawrousek EF. Single-strand DNA-mediated targeted mutagenesis of genomic DNA in early mouse embryos is stimulated by Rad51/54 and by Ku70/86 inhibition. Gene Ther. [Internet]. 2008;15:468–472. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18079752
- Igoucheva O, Alexeev V, Scharer O, et al. Involvement of ERCC1/XPF and XPG in Oligodeoxynucleotide-directed Gene Modification. Oligonucleotides. [Internet]. 2006;16:94–104. .
- Olsen PA, Randol M, Luna L, et al. Genomic sequence correction by single-stranded DNA oligonucleotides: role of DNA synthesis and chemical modifications of the oligonucleotide ends. J Gene Med. [Internet]. 2005;7:1534–1544. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16025558
- Ferrara L, Parekh-Olmedo H, Kmiec EB. Enhanced oligonucleotide-directed gene targeting in mammalian cells following treatment with DNA damaging agents. Exp Cell Res. [Internet]. 2004;300:170–179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15383324
- Wu X-S, Xin L, Yin W-X, et al. Increased efficiency of oligonucleotide-mediated gene repair through slowing replication fork progression. Proc Natl Acad Sci U S A. [Internet]. 2005;102:2508–2513. Available from: http://www.pnas.org/content/102/7/2508.short
- Ferrara L, Kmiec EB. Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination. Nucleic Acids Res. [Internet]. 2004;32:5239–5248. Available from: http://nar.oxfordjournals.org/content/32/17/5239.long
- Jinek M, Chylinski K, Fonfara I, et al. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. [Internet]. 2012;337:816–821. .
- Jinek M, East A, Cheng A, et al. RNA-programmed genome editing in human cells. Elife. [Internet]. 2013;2:e00471. Available from: http://elifesciences.org/content/2/e00471.abstract
- Cho SW, Kim S, Kim JM, et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. [Internet]. 2013;31:230–232. Available from: http://www.nature.com/articles/nbt.2507
- Cong L, Ran FA, Cox D, et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. [Internet]. 2013;339:819–823. .
- Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823–826.
- Rivera-Torres N, Banas K, Kmiec EB. Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing. Leuk Lymphoma. [Internet]. 2020;61:3078–3088. .
- García-Tuñón I, Hernández-Sánchez M, Ordoñez JL, et al. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget. [Internet]. 2017;8:26 027–26040. .
- Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. [Internet]. 2015;7:303ra139–303ra139. .
- Salas-Mckee J, Kong W, Gladney WL, et al. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy. Hum Vaccin Immunother. [Internet]. 2019;15:1126–1132. .
- Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. [Internet]. 2018;24:563–571. Available from: http://www.nature.com/articles/s41591-018-0010-1
- Ren J, Zhang X, Liu X, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. [Internet]. 2017;8:17002–17011. .
- Turnis ME, Andrews LP, Vignali DAA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. [Internet]. 2015;45:1892–1905. .
- Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. [Internet]. 2010;207:2187–2194. Available from: https://rupress.org/jem/article/207/10/2187/40732/Targeting-Tim3-and-PD1-pathways-to-reverse-T-cell
- Odorizzi PM, Wherry EJ. Inhibitory Receptors on Lymphocytes: insights from Infections. J Immunol. [Internet]. 2012;188:2957–2965. .
- Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. Longo DL, editor. N Engl J Med. [Internet]. 2018;378:158–168. .
- Zhang T, Somasundaram R, Berencsi K, et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol. [Internet]. 2006;36:457–467. .
- Bialk P, Wang Y, Banas K, et al. Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells In Vitro and in a Xenograft Mouse Model. Mol Ther - Oncolytics. [Internet]. 2018;11:75–89. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2372770518300263
- Gao Q, Dong X, Xu Q, et al. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy. Cancer Med. [Internet]. 2019;8:4254–4264. .
- NIH Clinical Trials Database [Internet]. cited 2021 Mar 3. Available from: https://clinicaltrials.gov/.
- Snyder J, Falcetti C, Goldberg I. bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) [Internet]. 2021. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-temporary-suspension-phase-12-and-phase-3. Accessed: March 1, 2021.
- Kmiec E, Marron J. Potential Inequities in New Medical Technologies. Sci Am. [Internet]. 2020 Mar 28. Available from: https://blogs.scientificamerican.com/observations/potential-inequities-in-new-medical-technologies/